FDA meeting supported Mirum Pharmaceuticals' drug launch, and the company reported earnings on Nasdaq.
2 reports, 2 independent
Updated Aug 5
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA meeting supported Mirum Pharmaceuticals' drug launch, and the company reported earnings on Nasdaq.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Mirum Pharmaceuticals received FDA support for drug launch and reported earnings.1 source
Mirum Pharmaceuticals is seeking product launch approval from the FDA for its targets in Europe.1 source
Keep exploring
The entities involved
- FDA
-
Mirum Pharmaceuticals
biopharmaceutical company
-
Nasdaq
American fully electronic stock exchange
Related events
- Iovance Biotherapeutics listed its stock on Nasdaq and received Fast Track designation from the FDA.
- Decoy Therapeutics is listed on the Nasdaq stock exchange and is currently seeking expedited regulatory approval via FDA pathways.
- Rocket is utilizing Nasdaq for investor evaluation and the FDA reviewed Phase 2 efficacy data for its product RP-A501.
- Alvotech utilized Nasdaq for its public stock listing and is currently undergoing comprehensive review by the FDA for biosimilar applications.
- Cardiol Therapeutics Inc. is listed on Nasdaq and is developing therapy for an FDA-approved indication.